copper required oncogenic braf signalling tumorigenesis
braf kinase mutated typically val > glu v600e induce active oncogenic state large fraction melanomas thyroid cancers hairy cell leukaemias smaller extent wide spectrum cancers brafv600e phosphorylates activates mek1 andmek2 kinases turn phosphorylate activate erk1 erk2 kinases stimulating mitogen-activated protein kinase mapk pathway promote cancer targeting mek1/ proving important therapeutic strategy given mek1/ inhibitor provides survival advantage metastatic melanoma effect increased administered together brafv600e inhibitor previously found copper cu influx enhances mek1 phosphorylation erk1/ cu-mek1 interaction show decreasing levels ctr1 cu transporter mutations mek1 disrupt cu binding decreased brafv600e-driven signalling tumorigenesis mice human cell settings conversely mek1-mek5 chimaera phosphorylated erk1/ independently cu active erk2 restored tumour growth murine cells lacking ctrl1 cu chelators used treatment wilson disease decreased tumour growth human murine cells transformed brafv600e engineered resistant braf inhibition taken together results suggest cu-chelation therapy repurposed treat cancers containing brafv600e mutation
